Clinical Guides
Haemophilia
A clinically focused clinical guide to haemophilia recognition, laboratory confirmation, bleed prevention, inhibitor care, genetic counselling, and safe referral across Indian health systems.
MedNext Academy | 15 min read
Haemophilia
A clinically focused clinical guide to haemophilia recognition, laboratory confirmation, bleed prevention, inhibitor care, genetic counselling, and safe referral across Indian health systems.
Summary
Haemophilia A and B are inherited bleeding disorders caused by deficiency or dysfunction of coagulation factor VIII and factor IX respectively. They usually follow X-linked inheritance, so most people with clinically significant disease are male, while females with an F8 or F9 variant may have reduced factor activity and clinically important bleeding. Severity is traditionally classified by baseline factor activity: severe below 1 IU/dL, moderate 1–5 IU/dL, and mild above 5 to below 40 IU/dL. The laboratory category predicts bleeding tendency at population level, but an individual's phenotype also reflects joints, trauma, treatment exposure, inhibitor status, comorbidity and access to care.
Deep muscle and joint bleeding is characteristic of severe disease. Recurrent haemarthrosis causes synovitis, cartilage loss, contracture, pain and disability. Intracranial, neck, gastrointestinal, iliopsoas and other closed-space bleeds can be fatal. Mild haemophilia may first become apparent after dental extraction, surgery or major injury. Diagnosis requires a personal and family bleeding history, screening coagulation tests, specific factor assays and exclusion of von Willebrand disease or an acquired inhibitor. A normal family history does not exclude a new variant, maternal transmission through an unrecognised carrier, or a symptomatic female.
Modern care prioritises prevention rather than repeated rescue treatment. Regular prophylaxis with an appropriate factor concentrate or a non-factor therapy, rapid treatment of breakthrough bleeding, comprehensive musculoskeletal care, inhibitor surveillance and planned surgery can preserve function. Product choice, dose and access are specialist decisions. Gene therapy is not a universal cure and has eligibility, durability, monitoring, cost and regulatory limitations. This educational draft remains quarantined following MedNext Clinical Team review and cannot replace a haemophilia treatment centre plan or emergency factor protocol.
How Common Is It?
Haemophilia occurs worldwide. Haemophilia A is more common than haemophilia B, and severe disease represents only part of the total diagnosed population. The World Federation of Hemophilia Annual Global Survey records people known to participating treatment organisations rather than conducting population-wide case finding. Its country tables are therefore valuable service indicators but not complete prevalence censuses. Underdiagnosis is greatest in people with mild disease, females, people distant from specialised laboratories and families in which early bleeding deaths prevented a formal diagnosis.
India has a large absolute burden because of its population, but the number registered with treatment organisations cannot be treated as the number living with haemophilia. State coverage, diagnostic capacity, treatment-centre participation and data quality vary. A reported count may rise because ascertainment improves, not because incidence has changed. Conversely, a low district count may signal unmet diagnostic need. For service planning, useful measures include confirmed diagnosis by type and severity, age distribution, inhibitor prevalence, annual bleeding rate, target-joint burden, factor or non-factor access, emergency treatment delay, surgery demand and loss to follow-up.
Carrier frequency and female bleeding are also incompletely represented in registries structured around affected males. Each family may contain several people who need counselling, factor testing or molecular clarification. Population averages cannot predict one person's bleed risk, and registry membership must never become a condition for emergency care. Clinicians should document local denominators and the distinction between identified, actively followed and comprehensively treated patients. The epidemiological evidence supports systematic detection and durable registries, but it does not justify an exact universal Indian prevalence claim or an assumption of equal access across public, charitable and private services.
Risk Factors
The primary cause is a pathogenic variant affecting F8 or F9. A maternal family history of affected males raises suspicion, yet roughly one family may have no recognised history because of a new variant, small family size, incomplete penetrance in females or missed diagnoses. A person assigned female at birth can have low factor activity because of lyonisation, Turner syndrome, homozygosity or compound heterozygosity, or other unusual genetic circumstances. Bleeding symptoms and measured factor level—not sex alone—should determine evaluation. Genetic counselling should be voluntary, confidential, non-directive and alert to family, insurance and social consequences.
Among people with haemophilia, untreated severe deficiency, delayed access to replacement, recurrent haemarthrosis, established target joints and high-risk activity increase morbidity. Intracranial bleeding risk rises with head injury and may be compounded by hypertension or medicines affecting haemostasis. Surgery, dental extraction, intramuscular injection and invasive procedures require advance cover. Antiplatelet agents, anticoagulants and non-steroidal anti-inflammatory drugs can worsen bleeding; they are not automatically forbidden, because cardiovascular indications may outweigh risk, but prescribing needs a jointly documented plan.
Development of a neutralising inhibitor is a major treatment complication. Risk is greatest during early exposure days in severe haemophilia A and is influenced by genotype, family history and treatment context. An unexpectedly poor clinical or factor-recovery response is a warning. Infection transmission from contemporary virally inactivated or recombinant products is far lower than historically, but older recipients may carry hepatitis B, hepatitis C or HIV and require appropriate testing and care. Obesity, low physical activity, chronic synovitis, dental disease, limited physiotherapy and interrupted prophylaxis amplify disability. Risk assessment must include treatment availability, travel time, cold-chain reliability, school or workplace barriers and the patient's ability to recognise and immediately report dangerous bleeds.
Diagnosis
History
Ask about prolonged bleeding after heel prick, circumcision, injections, tooth eruption, trauma, surgery or dental work; spontaneous joint swelling; deep muscle pain; large bruises; epistaxis; oral bleeding; haematuria; gastrointestinal bleeding; and symptoms after head injury. Record age at first bleed, sites, frequency, treatment response and transfusion exposure. Build a three-generation pedigree that follows the maternal line without treating an absent history as exclusion. In females, ask about heavy menstrual bleeding, postpartum haemorrhage and procedural bleeding. Document medicines, liver or renal disease and any prior factor activity, inhibitor result or genetic report.
Examination
During an acute event, assess airway, circulation, neurological state, pain and the anatomical compartment before a routine musculoskeletal examination. Inspect swelling, warmth, guarded posture and loss of range without forceful manipulation. Iliopsoas bleeding may cause groin pain, hip flexion and femoral neuropathy; neck or tongue swelling threatens the airway. Between bleeds, document joints, gait, muscle strength, contractures, chronic pain, oral health, skin and evidence of liver disease. A normal examination between episodes does not exclude mild haemophilia.
Investigations
Obtain complete blood count, prothrombin time, activated partial thromboplastin time and fibrinogen, while remembering that mild factor deficiency may not prolong the aPTT and reagent sensitivity varies. Perform one-stage or chromogenic factor VIII and IX assays in a quality-assured laboratory; discordance can be diagnostically important. Low factor VIII requires evaluation for von Willebrand disease. A mixing study can support factor deficiency versus inhibitor but does not replace a specific assay or Bethesda-type inhibitor measurement. Sample timing, heparin contamination, lupus anticoagulant, recent factor infusion and emicizumab can confound results; emicizumab shortens aPTT and invalidates conventional aPTT-based factor VIII assays. Molecular testing confirms the familial variant, supports carrier and prenatal options, and must follow counselling. Never delay emergency haemostatic treatment for imaging or complete laboratory confirmation when a dangerous bleed is clinically suspected.
Differential Diagnosis
Von Willebrand disease is the most important inherited alternative, particularly with low factor VIII, mucocutaneous bleeding or affected males and females across generations. It results from quantitative or qualitative von Willebrand factor abnormality and requires antigen, activity and factor VIII interpretation. Other congenital factor deficiencies can prolong the aPTT, including factor XI deficiency; factor XII, prekallikrein and high-molecular-weight kininogen deficiencies may markedly prolong aPTT without causing bleeding. Combined factor deficiencies, platelet-function disorders and fibrinogen disorders should be considered when the phenotype and initial tests disagree.
An acquired factor VIII inhibitor can mimic haemophilia A, often presenting in an older adult, postpartum patient or person with autoimmune disease or malignancy who has no lifelong history. The aPTT may fail to correct after incubation, but formal inhibitor testing and specialist interpretation are required. Lupus anticoagulant usually associates with thrombosis rather than bleeding, although coexistence with hypoprothrombinaemia or another defect is possible. Unfractionated heparin, direct oral anticoagulants and sample contamination can produce misleading screening results. Liver disease, vitamin K deficiency and disseminated intravascular coagulation usually affect multiple factors and commonly alter PT, platelet count or fibrinogen as well.
For an acutely swollen painful joint, distinguish haemarthrosis from septic arthritis, fracture, ligament injury, gout, inflammatory arthritis and synovial disease. Fever does not reliably distinguish infection from bleeding, and aspiration in suspected haemophilia requires haemostatic planning. Iliopsoas bleeding may resemble appendicitis, hip pathology, renal colic or psoas abscess. Intracranial bleeding can initially resemble concussion or migraine. Easy bruising in a child also raises non-accidental injury, but inherited bleeding and inflicted injury can coexist; safeguarding assessment should be careful and multidisciplinary. A diagnostic label should integrate phenotype, repeat factor measurement, inhibitor status and molecular data rather than rest on one prolonged aPTT.
Management
Treat suspected life-, limb- or organ-threatening bleeding immediately according to the person's emergency plan, then confirm anatomy and monitor response. Factor VIII or IX concentrate remains central for replacement therapy; product, target activity, dose, interval and duration depend on haemophilia type, severity, site, pharmacokinetics, inhibitor status and local protocol. Do not wait for a CT scan before haemostatic cover in suspected intracranial bleeding. Rest, protected mobilisation, ice used carefully, compression where appropriate and elevation may support joint care, but factor or non-factor haemostasis and specialist reassessment are decisive. Avoid repeated aspirations unless infection or severe pressure creates a specialist indication.
For severe haemophilia A or B, long-term prophylaxis is preferred to episodic treatment because preventing bleeding protects joints and quality of life. Standard- or extended-half-life factor concentrates can be individualised by bleeding pattern and pharmacokinetics. Emicizumab prophylaxis is an option for haemophilia A with or without factor VIII inhibitors; it does not treat every acute bleed and changes laboratory interpretation. People with inhibitors may need bypassing agents and immune-tolerance approaches. Concomitant activated prothrombin complex concentrate with emicizumab has a recognised thrombotic microangiopathy and thrombosis risk, so emergency plans must specify the correct bypassing strategy.
Comprehensive care includes physiotherapy, safe physical activity, joint imaging when indicated, pain management, dental prevention, vaccination, psychosocial support, education, transition and reproductive counselling. Surgery belongs in an experienced centre with a written factor and laboratory plan extending through rehabilitation. Desmopressin may help selected patients with mild haemophilia A after a documented response trial; it is ineffective in haemophilia B. Antifibrinolytics are useful for many oral or mucosal bleeds but unsuitable in some urinary-tract situations. Gene therapy and newer rebalancing agents require regulatory eligibility, specialist consent and long-term surveillance. No international recommendation establishes Indian funding, availability or an individual prescription.
Prescribing Information
Haemostatic therapy should be prescribed from a named emergency or prophylaxis protocol. For factor concentrate, record the exact product, potency units, indication, calculated dose, timing, expected recovery, repeat schedule and monitoring. Factor VIII dosing commonly uses body weight and desired activity rise, while factor IX recovery is product-specific; these principles do not justify a universal dose in an educational page. Children, people with obesity, major bleeds, surgery and altered pharmacokinetics need individualisation. Verify product labels and Indian regulatory information because formulations, half-life claims, age authorisations and storage requirements differ.
Desmopressin can release endogenous factor VIII and von Willebrand factor in responsive mild haemophilia A. Test response in a stable setting before relying on it for a procedure. Tachyphylaxis, fluid retention and hyponatraemia limit repeated dosing; young children, older adults and people with cardiovascular disease need special caution. Tranexamic acid supports oral, nasal and menstrual haemostasis, but renal adjustment, thrombotic context and haematuria or upper urinary-tract bleeding require assessment. Avoid intramuscular routes when safer alternatives exist. Analgesia usually begins with paracetamol; non-steroidal anti-inflammatory use requires haemophilia-team advice.
Emicizumab is administered subcutaneously for prophylaxis in haemophilia A. It interferes with aPTT and one-stage factor VIII assays, so the laboratory must know the treatment and use appropriate chromogenic methods when needed. It is not factor VIII and does not normalise every haemostatic challenge. Bypassing-agent selection during breakthrough bleeding must follow the treatment centre's plan. Gene therapy involves vector-specific eligibility, liver assessment, corticosteroid and transaminase monitoring, uncertainty about durability and reproductive precautions. Anticoagulation or antiplatelet therapy may be necessary for a strong cardiovascular indication but requires joint haematology and prescribing-specialty oversight. Patients should carry diagnosis, inhibitor, product and emergency contact information; substitutions during shortage should never be improvised without confirming efficacy and safety.
When to Refer
Refer any person with unexplained recurrent bleeding, isolated prolonged aPTT, low factor VIII or IX, or a suggestive family history to a haemostasis service. A child with early deep-tissue or joint bleeding needs expedited assessment. Females with low factor levels or a clinically important bleeding phenotype deserve the same diagnostic seriousness as males. Carrier testing and predictive molecular testing should follow counselling, informed consent and confirmation of the familial variant where possible. Mild disease still needs a treatment-centre link before dental extraction, childbirth, surgery or high-risk activity.
People with confirmed haemophilia benefit from comprehensive-centre follow-up even when routine treatment occurs locally. Refer for prophylaxis design, pharmacokinetic adjustment, inhibitor surveillance, recurrent breakthrough bleeding, target-joint assessment, chronic pain, planned procedures and transition between paediatric and adult services. An unexpectedly low factor recovery, shortened half-life or poor clinical response requires urgent inhibitor evaluation. Surgery, neuraxial procedures and invasive diagnostics require a written haemostatic plan shared with anaesthesia, surgery, laboratory, blood bank, pharmacy and physiotherapy. Pregnancy in a carrier needs obstetric-haematology coordination, fetal-sex and genetic discussions where desired, and a maternal and neonatal delivery plan.
Emergency transfer is required for suspected intracranial, spinal, neck, throat, thoracic, abdominal, iliopsoas or major muscle bleeding; threatened compartment syndrome; major trauma; uncontrolled bleeding; shock; new focal neurology; or anaphylaxis. Give indicated haemostatic treatment before transfer when locally available and do not allow referral logistics to create avoidable delay. In India, verify that the receiving facility actually has the required factor or bypassing agent, assay capability, imaging, critical care and specialist contact. A paper referral without product continuity can be unsafe. Telephonic haemophilia-centre advice and a patient-held plan are valuable bridges, but they do not replace examination when a serious bleed is possible.
Red Flags
Any head injury followed by headache, vomiting, drowsiness, seizure, confusion, visual change or focal deficit is intracranial bleeding until urgently assessed. Treat first according to the emergency haemostasis plan and image promptly. Neck or tongue swelling, dysphagia, stridor or voice change threatens the airway. Chest pain, dyspnoea, haemoptysis, abdominal distension, persistent abdominal pain, melaena, haematemesis or circulatory instability may indicate concealed or major bleeding. Back, groin or lower-abdominal pain with hip flexion, weakness or altered anterior-thigh sensation suggests iliopsoas bleeding and femoral-nerve compression.
A tense painful limb, escalating analgesic requirement, paraesthesia, pallor or reduced pulses raises compartment syndrome. A hot swollen joint with systemic illness may be septic arthritis, which can coexist with haemarthrosis. Haematuria with colic, clot retention or falling haemoglobin needs urgent urological and haemostasis assessment; antifibrinolytic therapy can worsen obstructing urinary clots. Prolonged oral bleeding can compromise the airway or signal inadequate treatment. Infants may show irritability, reduced limb movement, scalp swelling or unexplained anaemia rather than describing pain.
Treatment-related red flags include urticaria, wheeze, hypotension or collapse during factor infusion; poor response to an adequate dose; and new bleeding despite adherence, which may indicate an inhibitor or wrong diagnosis. On emicizumab, a breakthrough bleed treated with activated prothrombin complex concentrate requires strict specialist oversight because cumulative exposure can cause thrombosis or thrombotic microangiopathy; abdominal pain, confusion, renal dysfunction, limb swelling or respiratory symptoms warrant urgent review. After gene therapy, rising transaminases, jaundice or loss of factor expression requires the gene-therapy centre. Fever after central venous access manipulation may represent line infection. Emergency clinicians should contact the treatment centre but must not postpone stabilisation while awaiting records.
Indian Clinical Context
Haemophilia services in India range from comprehensive public and teaching-hospital centres to episodic emergency provision, charitable supply and out-of-pocket purchase. Availability of factor concentrates, emicizumab, inhibitor assays, genetic testing, physiotherapy and home treatment differs by state and institution. WFH recommendations define global best-practice aims; they are not an Indian reimbursement schedule and do not prove that a particular product is licensed, stocked or funded locally. Every plan should name a primary treatment centre, a reachable emergency facility and an alternative during shortage or travel.
A patient-held record can prevent dangerous repetition and delay. It should state haemophilia type and severity, baseline factor level, inhibitor history, current prophylaxis, usual acute-bleed product, allergies, venous access, prior reactions and treatment-centre contacts. Families need practical teaching in the language they use, including bleed recognition, storage, reconstitution and sterile administration if home therapy is authorised. Schools and employers should support safe participation rather than impose blanket exclusion. Physiotherapy and dental prevention reduce future cost and disability and should not be treated as optional luxuries.
Carrier and prenatal services require particular care. Testing must be voluntary and non-directive, with privacy safeguards and an explanation that factor activity alone does not reliably establish carrier status. Prenatal diagnosis, preimplantation testing and fetal-sex determination interact with law, availability, values and cost; referral must follow current Indian legal and institutional requirements without facilitating unlawful sex selection. Blood-borne virus screening and vaccination remain important for older recipients and anyone exposed to plasma products. Rural transfer plans should include factor before prolonged transport when indicated. The evidence base contains limited Indian comparative outcome and access data, so local audit should report treatment delays, missed prophylaxis, annual bleed and joint outcomes rather than claim international-equivalent coverage.
NMC Competency Mapping
The NMC Competency Based Medical Education Curriculum 2024 places haemophilia within Pathology Topic 20. PA20.1 asks learners to describe normal haemostasis and classify and explain the aetiology, pathogenesis and pathology of vascular and platelet disorders including haemophilia. PA20.2 covers disseminated intravascular coagulation and vitamin K deficiency, which are important contrasting causes of abnormal coagulation. Blood-bank outcomes PA21.1 to PA21.6 provide supporting knowledge about components, transfusion-transmitted infection, reactions, autologous transfusion, blood grouping and cross-matching.
An undergraduate should connect factor VIII deficiency with haemophilia A and factor IX deficiency with haemophilia B; explain X-linked inheritance without excluding symptomatic females; distinguish deep-tissue and joint bleeding from predominantly mucocutaneous bleeding; interpret PT, aPTT, mixing studies and specific factor assays; and recognise that mild disease can have a normal screening aPTT. They should identify intracranial, airway, iliopsoas and compartment bleeds as emergencies, understand the purpose of prophylaxis, and know that inhibitors cause inadequate response to replacement. They should not infer a treatment dose from severity alone.
Integrated teaching should link pathology, paediatrics, medicine, orthopaedics, obstetrics, genetics, pharmacology, dentistry, laboratory medicine and transfusion practice. Suitable assessments include a boy with recurrent knee swelling, a woman with procedure-related bleeding and low factor VIII, an isolated prolonged aPTT, or a treated patient with unexpectedly poor recovery. Learners should formulate immediate stabilisation, essential tests and referral. Curriculum knowledge does not credential independent factor prescribing, bypassing-agent selection, inhibitor quantification, prenatal counselling, surgery cover or gene-therapy assessment; these require supervised specialist practice and current institutional protocols.
Key Exam Pearls for NEET PG
Haemophilia A is factor VIII deficiency and haemophilia B is factor IX deficiency. Both usually show X-linked inheritance, deep-tissue bleeding, haemarthrosis and an isolated prolonged aPTT, with normal PT and platelet count. Severe disease has baseline activity below 1 IU/dL, moderate disease 1–5 IU/dL and mild disease above 5 to below 40 IU/dL. Screening aPTT can be normal in mild deficiency. A mixing study that corrects supports deficiency; time-dependent failure to correct raises an inhibitor, but a factor assay and inhibitor measurement are definitive.
Factor VIII also falls in von Willebrand disease because von Willebrand factor carries it. Mucosal bleeding, autosomal family patterns and abnormal von Willebrand factor testing favour that diagnosis. Haemarthrosis most often affects knees, ankles and elbows. Recurrent bleeding causes chronic synovitis and haemophilic arthropathy. Iliopsoas haemorrhage produces hip flexion and may compress the femoral nerve. Suspected intracranial or airway bleeding requires haemostatic treatment before diagnostic delay.
Desmopressin may help responsive mild haemophilia A but does not treat haemophilia B. Tranexamic acid is useful for many mucosal bleeds but can be hazardous in upper urinary-tract bleeding. Factor replacement can provoke neutralising inhibitors, especially early in severe haemophilia A. Emicizumab is bispecific prophylaxis for haemophilia A; it shortens aPTT, makes aPTT-based factor VIII testing unreliable and is not an acute factor substitute. Activated prothrombin complex concentrate combined with emicizumab can cause thrombosis or thrombotic microangiopathy. For NMC, anchor haemophilia to PA20.1 and connect blood-component safety to PA21. Prophylaxis prevents bleeds and joint damage; episodic rescue does not reverse established arthropathy.
Frequently Asked Questions
Can a girl or woman have clinically important haemophilia-related bleeding?
Yes. Females carrying an F8 or F9 variant can have reduced factor activity because of X-chromosome inactivation and may experience heavy menstrual, postpartum, surgical or spontaneous bleeding. Rare genetic circumstances can cause severe disease. Symptoms and factor activity deserve direct assessment; the label carrier must not be used to dismiss bleeding.
Should treatment wait for imaging after a person with haemophilia hits their head?
No when a clinically significant intracranial bleed is suspected. The person's emergency haemostatic plan should be activated promptly, followed by imaging, neurological observation and specialist care. A normal early appearance does not reliably exclude bleeding. Product selection is different when an inhibitor or non-factor prophylaxis is present, so contact the treatment centre without delaying stabilisation.
Does emicizumab cure haemophilia A or make all coagulation tests normal?
No. Emicizumab reduces bleeding through factor VIII-mimetic activity but does not remove the F8 variant, treat every breakthrough bleed or provide normal haemostasis for every procedure. It markedly affects aPTT and aPTT-based factor VIII assays. The laboratory and emergency team must know it is being used and follow an assay- and product-specific plan.
Can international haemophilia guidelines be used as an Indian prescription or funding promise?
No. WFH guidance provides global evidence-informed standards, but Indian licensing, procurement, public entitlement, storage, laboratory access and specialist capacity vary. A treatment centre must translate the principles into a patient-specific plan using locally authorised products and monitoring. Where recommended therapy is unavailable, the limitation and safest feasible referral pathway should be documented explicitly.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic